Clinical trials: Hepatic and Hepatobiliary Disorders, active
NAFLD, Diabetes
DIAbetes and NAFLD
Non-alcoholic hepatic steatosis (NAFLD) is characterised by the excessive accumulation of triglycerides in the liver and is often associated, in the absence of significant alcohol consumption, with insulin resistance and…
- Conditions
- NAFLD, Diabetes, NASH, Fibrosis, Liver
- Trial name
- DIANA (NCT06315361)
- Where
- Italy
- Volunteers
- 600 people
- Sponsor
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Liver Transplantation
Assessment of a Quantra-guided Transfusion Algorithm in Liver Transplantation
Liver transplantation carries a substantial risk of bleeding, making precise haemostasis control essential, although assessing coagulation remains challenging.
- Trial name
- QUALIVERT (NCT06749405)
- Testing
- Transfusion algorithm based on Quantra®, Conventional transfusion algorithm
- Where
- France
- Volunteers
- 56 people
- Sponsor
- University Hospital, Toulouse
Type 1 Diabetes, Liver Steatoses
Prevalence and Risk Factors of Metabolic-Associated Hepatic Steatosis in Individuals Living With Type 1 Diabetes
The goal of this observational cross-sectional study is to assess the prevalence and stage of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD), specifically liver steatosis and fibrosis in adults aged 18 and older…
- Conditions
- Type 1 Diabetes, Liver Steatoses, MASLD - Metabolic Dysfunction-Associated Steatotic Liver Disease, Liver Fibrosis
- Trial name
- STEA-DT1 (NCT07475962)
- Testing
- Adiposity and BMI Classification
- Volunteers
- 100 people
- Sponsor
- Institut de Recherches Cliniques de Montreal
Autoimmune Liver Disease, Liver Transplant Disorder
A Study of SIPLIZUMAB in AILD and LT Patients
There is a significant unmet need for safe and effective therapeutic approaches to prevent immune-mediated graft injury and its complications in liver transplant (LT) recipients with autoimmune liver disease (AILD) including…
- Conditions
- Autoimmune Liver Disease, Liver Transplant Disorder, Autoimmune Hepatitis, Primary Sclerosing Cholangitis
- Trial name
- SET-SAIL (NCT06455280)
- Testing
- Siplizumab
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- Elizabeth C. Verna
End Stage Liver Disease, Hepatocellular Carcinoma
Vienna Hypothermic Oxygenated Machine Perfusion Study
In this observational cohort study data on all patients undergoing liver transplantation after hypothermic oxygenated machine perfusion at Medical University of Vienna will be prospectively recorded.
- Trial name
- VIHOMPS (NCT06418165)
- Where
- Austria
- Volunteers
- 500 people
- Sponsor
- Medical University of Vienna
Crohn Disease, Ulcerative Colitis
Safety and Efficacy of Fecal Microbiota Transplantation
The gut microbiota is critical to health and functions with a level of complexity comparable to that of an organ system. Dysbiosis, or alterations of this gut microbiota ecology, have been implicated in a number of disease…
- Conditions
- Crohn Disease, Ulcerative Colitis, Celiac Disease, Irritable Bowel Syndrome
- Trial name
- NCT04014413
- Testing
- Fecal Microbiota Transplantation
- Where
- Hong Kong
- Volunteers
- 450 people
- Sponsor
- Chinese University of Hong Kong
Hepatic Impairment, Healthy, Hepatic Insufficiency
A Study to Learn How the Study Medicine Called Atirmociclib is Handled by the Body in People With Normal Liver Function and Different Levels of Liver Disease
The purpose of this study to understand how the study medicine atirmociclib behaves in the body and how safe it is for people with different levels of liver health.
- Conditions
- Hepatic Impairment, Healthy, Hepatic Insufficiency, Healthy Adults
- Trial name
- NCT07677358
- Testing
- Atirmociclib
- Where
- 3 sites in United States
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- Pfizer
MASLD - Metabolic Dysfunction-Associated Steatotic Liver Disease, Overweight
EVOO and Metabolic Liver Health in MASLD
MASLD is currently one of the most common chronic non-communicable diseases and the leading cause of liver-related mortality and morbidity, with a rising prevalence worldwide, especially in the presence of obesity, diabetes, and…
- Trial name
- EvoLiveR (NCT07412444)
- Testing
- Oil Supplementation - 3 tablespoons of oil, 9 Tablespoons of Oil
- Where
- Italy
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Azienda Ospedaliera Specializzata in Gastroenterologia Saverio de Bellis
End-stage Liver Disease, Liver Cirrhosis
Nutrition and Exercise Prehabilitation in Patients Awaiting Liver Transplantation
This study aims to evaluate the effects of a diet with even protein distribution plus exercise (Group A) versus a diet with skewed protein distribution plus exercise (Group B) versus standard dietary and physical activity advice…
- Conditions
- End-stage Liver Disease, Liver Cirrhosis, Liver Transplantation, Malnutrition
- Trial name
- POWER-LT (NCT07561138)
- Testing
- Diet with even protein distribution plus exercise program, Diet with skewed protein distribution plus exercise program, Standard dietary and physical activity advice
- Where
- 2 sites in Greece
- Volunteers
- 90 people
- Sponsor
- Kalliopi Anna Poulia
Portal Hypertension
Non-Invasive Portal and Hepatic Vein Pressure Estimation
Background Portal hypertension (PH) is a spectrum of complications of end-stage liver disease (ESLD) and cirrhosis, with severe manifestations including ascites and gastroesophageal varices.
- Trial name
- NONEEDLES (NCT06210178)
- Testing
- Magnetic Resonance Imaging
- Where
- Netherlands
- Volunteers
- 50 people
- Sponsor
- Leiden University Medical Center
Cirrhosis, Ascites Hepatic
Using Bedside Ultrasound to Understand Fluid Management in Patients With Chronic Liver Disease
The goal of this observational study is to see if repeated bedside ultrasound measurements of the lungs and abdomen as well as a blood vessel in the neck can be done in patients with advanced liver disease and ascites (fluid in…
- Conditions
- Cirrhosis, Ascites Hepatic, Fluid Balance
- Trial name
- POCUS-C (NCT07810855)
- Testing
- Ultrasound measurement, Blood draw for the laboratory assessment
- Volunteers
- 100 people
- Sponsor
- Royal Free Hospital NHS Foundation Trust
Acute-on-Chronic Liver Failure (ACLF), Liver Cirrhosis
Evaluating Novel Scoring Systems to Predict Outcomes in Acute-on-Chronic Liver Failure
Acute-on-chronic liver failure (ACLF) is a serious condition where a patient with long-term liver disease suddenly experiences severe liver worsening and failure of other organ systems, such as the kidneys or lungs.
- Conditions
- Acute-on-Chronic Liver Failure (ACLF), Liver Cirrhosis, End Stage Liver Disease
- Trial name
- NCT07734896
- Volunteers
- 100 people
- Sponsor
- Assiut University
Cirrhosis, Microplastics
Microplastics, Cirrhosis and Portal Hypertension
Cirrhosis and portal hypertension are associated with an hyperdynamic circulation and hepatic inflammation, leading to complications like ascites, variceal bleeding, acute kidney injury, and higher infection risk.
- Conditions
- Cirrhosis, Microplastics, Portal Hypertension Related to Cirrhosis, Nanoplastics
- Trial name
- NCT07280390
- Testing
- Assessment of microplastics in tissue
- Where
- 2 sites in India
- Volunteers
- 30 people
- Sponsor
- Post Graduate Institute of Medical Education and Research, Chandigarh
End Stage Liver Disease
Allogenic Hepatocyte Transplantation Into Periduodenal Lymph Nodes
This Phase 2a clinical trial is a dose escalation study of the safety, tolerability, and efficacy of hepatocyte transplantation into lymph nodes via endoscopic ultrasound among subjects with end-stage liver disease.
- Trial name
- NCT04496479
- Testing
- LYG-LIV0001
- Where
- 2 sites in United States
- Volunteers
- 12 people
- Sponsor
- LyGenesis, Inc.
Metabolic Adaptation to High-Intensity Interval Training, Metabolic Associated-dysfunction Steatotic Liver Disease (MASLD)
Rehabilitation With Exercise-Based Intervention for Nonalcoholic Chronic Hepatic Esteatosis
This study proposes a single-blind randomized clinical trial designed to evaluate the effects of high-intensity interval training (HIIT) on liver health in adults with overweight or obesity, while also assessing the usefulness of…
- Trial name
- RENACE (NCT07552727)
- Testing
- High-intensity interval training
- Where
- Chile
- Volunteers
- 30 people
- Sponsor
- Universidad San Sebastián
Elastography, Shear Wave Elastography
HIBOC = Hepatic Imaging Biomarkers in Obese Children
The goal of this prospective, diagnostic observational study is to learn about how imaging based markers for components of liver disease appear in children with obesity.
- Conditions
- Elastography, Shear Wave Elastography, Shear Wave Dispersion, Attenuation Imaging
- Trial name
- NCT06463223
- Where
- Sweden
- Volunteers
- 300 people
- Sponsor
- Sahlgrenska University Hospital
Chronic Liver Disease, Alcohol Use Disorder
Nottingham Community Liver Biomarkers Cohort
Deaths due to advanced liver scarring (liver cirrhosis) continue to increase, and liver disease is now the 3rd leading cause of premature death in the United Kingdom.
- Conditions
- Chronic Liver Disease, Alcohol Use Disorder, Type 2 Diabetes, Persistently Elevated ALT
- Trial name
- NCT02037867
- Testing
- Fibrosis Biomarkers
- Where
- United Kingdom
- Volunteers
- 2,000 people
- Sponsor
- University of Nottingham
Non-alcoholic Steatohepatitis (NASH), Endoscopic Sleeve Gastroplasty
A Physiologic Analysis of Endoscopic Sleeve Gastroplasty (ESG)
Non-alcoholic fatty liver disease (NAFLD) is the most common chronic liver disease worldwide. Affecting approximately one-third of the United States (U.S.) population, the prevalence of NAFLD increases to 90% in patients with…
- Conditions
- Non-alcoholic Steatohepatitis (NASH), Endoscopic Sleeve Gastroplasty, Non-alcoholic Fatty Liver Disease (NAFLD), Endoscopic Ultrasound
- Trial name
- NCT04820036
- Testing
- Insulin Resistance, Quality of Life Assessment, Liver Function Test
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Brigham and Women's Hospital
Hepatic Steato-Fibrosis, Non-Alcoholic Fatty Liver Disease
MASLD in Primary Hypothyroidism and Efficacy of Dapaglifozin
Non-alcoholic fatty liver disease (NAFLD) is a global epidemic with a prevalence of 25-40%.Primary Hypothyroidism is one of Endocrinopathies who are at risk of developing NAFLD/NASH and estimated prevalence of Primary…
- Trial name
- SHIELD (NCT06373523)
- Testing
- Dapagliflozin 10mg Tab, Levothyroxine Replacement daily
- Where
- India
- Volunteers
- 50 people
- Sponsor
- Post Graduate Institute of Medical Education and Research, Chandigarh
Insulin Resistance, Prediabetic State
Human Models of Selective Insulin Resistance: Alpelisib, Part I
The goal of this clinical trial is to understand how the blood sugar-lowering hormone insulin works in healthy adults versus those who are at risk for type 2 diabetes.
- Conditions
- Insulin Resistance, Prediabetic State, Overweight and Obesity, Non-Alcoholic Fatty Liver Disease
- Trial name
- NCT06354088
- Testing
- Alpelisib 300 mg, [1-13C] sodium acetate, [6,6-2H2] D-glucose
- Where
- United States
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Columbia University